Bearberry / Uva Ursi

Arctostaphylos uva-ursi

Evidence Rating

C Moderate

Confidence Level

Moderate

Traditions

Western

Last Updated

2/9/2026

Summary

Bearberry (uva ursi) is the traditional European urinary antiseptic, with approval from all major European regulatory bodies for acute uncomplicated lower UTI. Its mechanism is unique: arbutin is converted to hydroquinone, which is excreted in urine and acts as a direct urinary antiseptic -- but only in alkaline urine (pH >7). This pH requirement is a significant practical limitation. Despite strong regulatory support, clinical trial evidence is surprisingly thin, with no published RCTs of bearberry monotherapy vs. antibiotic standard of care. Safety is acceptable but strictly time-limited: maximum 1-2 weeks of use, no more than 5 courses per year, due to hydroquinone's potential hepatotoxicity and theoretical carcinogenicity.

⚠️

Drug Interactions

This herb has significant drug interactions. Do not use if you are taking medications without consulting a healthcare provider first. See detailed interaction information below.

Regulatory Status

Regulatory Body	Status
Commission E (Germany)	✓ Approved
ESCOP (European)	✓ Approved
EMA/HMPC (EU)	✓ Approved

Metadata

Field	Details
Common Names	Bearberry, Uva Ursi (EN), Baerentraubenblatt (DE)
Botanical Name	Arctostaphylos uva-ursi (L.) Spreng.
Plant Family	Ericaceae (Heather family)
Part Used	Leaf (folium)
Drug Name	Uvae ursi folium
Evidence Quality Rating	Moderate (strong traditional basis; limited clinical trial evidence)

Approved Indications

Commission E (Germany)

Approved: Inflammatory disorders of the efferent urinary tract

ESCOP

Approved: Uncomplicated infections of the lower urinary tract such as cystitis, when antibiotic treatment is not considered essential

EMA/HMPC

Traditional Use: Relief of symptoms of mild, recurrent infections in the lower urinary tract, such as burning sensation when passing urine and/or frequently passing urine
Women only (traditional use registration specifies women aged 18+)
Only when serious conditions have been excluded by a medical doctor

WHO

Listed in WHO monographs for uncomplicated UTI

Agreement/Disagreement

Strong European consensus: All regulatory bodies (Commission E, ESCOP, HMPC, WHO) agree on the core indication — lower UTI
Important nuance: ESCOP specifies “when antibiotic treatment is not considered essential” — positioning bearberry as an alternative for mild cases, not a replacement for antibiotics in all UTIs
EMA/HMPC: More restrictive — traditional use only (not well-established use), and limited to women
US: Not FDA-approved; recognized in some naturopathic/integrative medicine contexts but not mainstream

Conditions Treated

Acute uncomplicated lower urinary tract infections (cystitis)
Recurrent mild UTI symptoms
Burning sensation during urination (dysuria)
Frequent urination associated with mild UTI
NOT indicated for: Upper UTIs (pyelonephritis), complicated UTIs, febrile UTIs, or UTIs in men

Mechanism of Action

Primary Mechanism: The Arbutin-Hydroquinone Pathway

Ingestion: Patient ingests bearberry leaf preparation containing arbutin (5-16% of dried leaf)
Absorption: Arbutin (hydroquinone-O-beta-D-glucopyranoside) is absorbed from the GI tract
Hepatic metabolism: Arbutin is hydrolyzed to hydroquinone (the active antimicrobial)
Conjugation: Hydroquinone is conjugated to glucuronide and sulfate esters (inactive transport forms)
Renal excretion: Conjugates are excreted in urine
Activation in urine: In alkaline urine (pH >7), bacterial beta-glucuronidase enzymes cleave the conjugates, releasing free hydroquinone at the site of infection
Antimicrobial action: Free hydroquinone acts as a direct antiseptic against common UTI pathogens

Critical pH Dependency

Alkaline urine (pH >7): Required for hydroquinone liberation and antimicrobial activity
Acidic urine: Hydroquinone remains conjugated and inactive
Practical implication: Patients should avoid acidifying foods (cranberry juice, vitamin C, acidic foods) and may be advised to alkalinize urine (sodium bicarbonate, vegetable-rich diet)
Maximum antibacterial effect: Reached approximately 3-4 hours after ingestion
Paradox: This means bearberry and cranberry work by OPPOSITE pH mechanisms and should NOT be used simultaneously

Key Bioactive Compounds

Arbutin (5-16%): Primary active compound; hydroquinone glycoside
Methylarbutin: Additional hydroquinone glycoside
Free hydroquinone (trace): Present in small amounts in the leaf
Gallotannins (15-20%): Astringent; may contribute to anti-inflammatory effect
Flavonoids: Quercetin glycosides (minor antimicrobial/anti-inflammatory)
Ursolic acid: Triterpene with anti-inflammatory activity
Allantoin: Promotes tissue repair

Antimicrobial Spectrum

Active against common UTI pathogens:
- Escherichia coli
- Proteus vulgaris
- Enterococcus faecalis
- Staphylococcus aureus
- Klebsiella pneumoniae
Activity demonstrated in vitro; in vivo clinical confirmation is limited

Clinical Evidence Summary

Published Clinical Studies

BRUMI Trial (Bearberry in Uncomplicated Cystitis)

Design: Multicentre, randomized, double-blind clinical trial
Status: Protocol published 2022 (PMC9234905); represents the first rigorous RCT of bearberry for UTI
Aim: To evaluate bearberry vs. placebo and vs. fosfomycin for acute uncomplicated cystitis
Significance: This trial is expected to provide the first high-quality evidence for or against bearberry in UTI
[NEEDS-RESEARCH: Results not yet published as of knowledge cutoff]

Observational/Traditional Evidence

Long history of traditional use across European pharmacopoeias (centuries of documented use)
No completed RCTs of bearberry monotherapy vs. antibiotics as of early 2025
Laboratory studies confirm antibacterial activity in vitro
One older German trial showed bearberry leaf extract reduced UTI recurrence compared to placebo over 12 months [UNCERTAIN — citation unclear]

Evidence Limitations

Major gap: No published RCTs comparing bearberry to antibiotic standard of care
In vitro antibacterial activity is well documented, but in vivo clinical efficacy trials are lacking
The pH dependency complicates trial design (urine pH must be controlled)
Most evidence is traditional/historical rather than clinical-trial-based
This is one of the most significant evidence gaps in European phytotherapy — a widely approved herb with thin clinical trial evidence

European vs US/Anglophone Consensus

Aspect	European Position	US/Anglophone Position
Regulatory status	Approved by Commission E, ESCOP, HMPC	Not FDA-approved; dietary supplement
Clinical role	Accepted alternative for mild uncomplicated UTI	Not widely recognized; niche use
Pharmacopoeia	In European Pharmacopoeia, German Pharmacopoeia	In USP-NF as dietary supplement monograph
Prescribing	Recommended by GPs/urologists for mild cystitis	Occasionally suggested by naturopaths
Antibiotic resistance context	Increasingly valued as antibiotic-sparing option	Growing interest but limited adoption

Safety Profile

Contraindications

Pregnancy (hydroquinone crosses placenta; theoretical teratogenic risk)
Lactation (hydroquinone excreted in breast milk)
Children under 12 years (HMPC) or under 18 years (some sources)
Severe liver disease
Severe kidney disease (impaired renal excretion of hydroquinone)
Known hypersensitivity to bearberry or Ericaceae family

Drug Interactions

Urinary acidifiers (vitamin C, cranberry, ammonium chloride): Antagonize bearberry’s mechanism by lowering urine pH
NSAIDs: Possible additive GI irritation
Drugs metabolized by CYP enzymes: No significant interactions documented
No major drug interactions established, but limited formal study

Side Effects

Common: Nausea, vomiting (due to high tannin content — minimized with food intake)
Occasional: GI discomfort, green-brown discoloration of urine (harmless)
Potential (with prolonged use): Hepatotoxicity from hydroquinone
Theoretical: Carcinogenicity with chronic hydroquinone exposure (basis for duration limits)

Duration Limits (Critical Safety Constraint)

Maximum duration per course: 1-2 weeks (most sources say 1 week; some allow up to 2 weeks)
Maximum frequency: No more than 5 courses per year
Rationale: Hydroquinone is a known hepatotoxin, irritant, and potential carcinogen at sustained high doses. The short-course limits keep cumulative exposure below toxicological concern thresholds
[Source: Garcia de Arriba et al., 2013 — risk assessment]

Pregnancy/Lactation

Contraindicated: Both HMPC and ESCOP prohibit use during pregnancy and lactation
Hydroquinone is potentially teratogenic
Oxytocic activity reported (theoretical risk of uterine stimulation)

Clinical Dosage

Standardized Dosage Forms

Form	Dosage	Notes
Dried leaf (tea/infusion)	3g in 150ml cold water, steeped 12-24h (cold maceration) or 10-15 min hot infusion; 3-4 cups daily	Cold maceration reduces tannin extraction, improving tolerability
Dry extract	Equivalent to 100-210mg arbutin, 2-3 times daily	EMA-recommended: maximum 800mg arbutin/day
Fluid extract (1:1)	1.5-4ml three times daily
Tincture (1:5)	2-4ml three times daily

Target Arbutin Dose

Daily arbutin intake: 400-840mg per day
Maximum: 800mg arbutin per day (HMPC)
Duration: Maximum 1-2 weeks

Practical Guidance for Urine Alkalinization

Sodium bicarbonate: 5g dissolved in water, taken with bearberry preparation
Vegetable-rich diet (reduces urinary acidity)
Avoid cranberry juice, vitamin C supplements, and acidic foods during bearberry use

Key Products

Arctuvan (Willmar Schwabe, Germany): Bearberry leaf dry extract
Cystinol akut (Schaper & Bruemmer, Germany): Bearberry extract dragees
Uvalysat (Germany): Liquid bearberry extract

Sources

Connections

See Cranberry for the contrasting UTI prevention herb (acidic mechanism vs. bearberry’s alkaline mechanism — do NOT combine)
See Goldenrod for irrigation therapy approach to UTI support